Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing

Abstract

Understanding of biosimilars is low, and educational needs are high. The information that clinicians deem important to assess, such as safety, efficacy and cost, will need to be provided before they are comfortable prescribing biosimilars.